Convatec 10-month trading update

AI SummaryClose X

Convatec reports YTD organic revenue growth ex-InnovaMatrix of 6.6% (3.7% including InnovaMatrix; reported 4.8%) with stronger H2 momentum—Infusion Care double-digit and Continence Care mid-to-high single-digit growth—and has upgraded FY26 Group organic revenue guidance to 6.25–7.0% (from 5.5–6.5%). The group reiterates adjusted operating margin of at least 23% (including c.65bps FX headwind and c.90bps InnovaMatrix drag) and double-digit adjusted EPS growth, expects InnovaMatrix FY26 revenue of c.$5m, targets total FY26 capex at the upper end of $200–230m (growth capex $135–165m), has c.$200m buyback on track, and expects adjusted net finance expense c.$75m with c.90% equity cash conversion.

Disclaimer*

UK 100

Latest directors dealings